Cargando…

The role of 18F–NaF PET/CT in metastatic bone disease

AIM: To investigate the role of 18F–NaF PET/CT and compare it with 99m Tc-MDP whole body bone scintigraphy and 18F-FDG PET/CT in detecting the extent of metastatic bone disease and to present our first experience with 18F–NaF PET/CT in our country. MATERIALS AND METHODS: A total of 37 histopathologi...

Descripción completa

Detalles Bibliográficos
Autores principales: Araz, Mine, Aras, Gülseren, Küçük, Özlem N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648995/
https://www.ncbi.nlm.nih.gov/pubmed/26587375
http://dx.doi.org/10.1016/j.jbo.2015.08.002
_version_ 1782401293635026944
author Araz, Mine
Aras, Gülseren
Küçük, Özlem N.
author_facet Araz, Mine
Aras, Gülseren
Küçük, Özlem N.
author_sort Araz, Mine
collection PubMed
description AIM: To investigate the role of 18F–NaF PET/CT and compare it with 99m Tc-MDP whole body bone scintigraphy and 18F-FDG PET/CT in detecting the extent of metastatic bone disease and to present our first experience with 18F–NaF PET/CT in our country. MATERIALS AND METHODS: A total of 37 histopathologically proven cancer patients (22 male, 15 female) with bone metastasis detected on Tc-99m MDP whole body bone scan were prospectively enrolled Cebeci, following ethics committee approval. 18F–NaF PET/CT was performed to the participants in Ankara University Medical Faculty Nuclear Medicine Department for evaluation of symptomatic skeletal sites which were negative on Tc-99m MDP whole body bone scan. A lesion based comparison was made between 18F–NaF PET/CT and Tc-99m MDP whole body bone scan for each patient and between 18F–NaF PET/CT and 18F-FDG PET/CT in 12/37 patients. RESULTS: The number of lesions demonstrated by 99m Tc-MDP bone scan and 18F–NaF PET/CT was equal in 4/37 (%11) of the cases. 18F–NaF PET/CT showed a greater number of pathological foci in 89% of participants. 18F–NaF PET/CT was able to show both lytic and blastic lesions and small lesions were better visualized due to the advantage of sectional imaging with much better resolution and higher target/background ratio. 18F–NaF PET/CT demonstrated a greater number of metastases in 10/12 (83%) of the patients when compared to 18F-FDG PET/CT. In the other two patients, bone metastasis could be demonstrated only by 18F–NaF PET/CT. The uptake of 18F-FDG was variable in blastic lesions and cranial bone involvement was missed by 18F-FDG PET/CT in some cases due to physiological brain metabolism. CONCLUSION: Although further prospective clinical studies in specific cancer populations are indicated to set the place of 18F–NaF PET/CT in diagnostic scheme, the results of this pilot study from our country support the superiority of 18F–NaF PET/CT in investigation of bone metastasis over 99mTc-MDP bone scan and 18F-FDG PET/CT in various malignancies. 18F–NaF PET/CT is coming forward as a single step bone seeking study, considering all the advantages, but especially potential of detecting occult metastases and reliably directing patient management.
format Online
Article
Text
id pubmed-4648995
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-46489952015-11-19 The role of 18F–NaF PET/CT in metastatic bone disease Araz, Mine Aras, Gülseren Küçük, Özlem N. J Bone Oncol Research Paper AIM: To investigate the role of 18F–NaF PET/CT and compare it with 99m Tc-MDP whole body bone scintigraphy and 18F-FDG PET/CT in detecting the extent of metastatic bone disease and to present our first experience with 18F–NaF PET/CT in our country. MATERIALS AND METHODS: A total of 37 histopathologically proven cancer patients (22 male, 15 female) with bone metastasis detected on Tc-99m MDP whole body bone scan were prospectively enrolled Cebeci, following ethics committee approval. 18F–NaF PET/CT was performed to the participants in Ankara University Medical Faculty Nuclear Medicine Department for evaluation of symptomatic skeletal sites which were negative on Tc-99m MDP whole body bone scan. A lesion based comparison was made between 18F–NaF PET/CT and Tc-99m MDP whole body bone scan for each patient and between 18F–NaF PET/CT and 18F-FDG PET/CT in 12/37 patients. RESULTS: The number of lesions demonstrated by 99m Tc-MDP bone scan and 18F–NaF PET/CT was equal in 4/37 (%11) of the cases. 18F–NaF PET/CT showed a greater number of pathological foci in 89% of participants. 18F–NaF PET/CT was able to show both lytic and blastic lesions and small lesions were better visualized due to the advantage of sectional imaging with much better resolution and higher target/background ratio. 18F–NaF PET/CT demonstrated a greater number of metastases in 10/12 (83%) of the patients when compared to 18F-FDG PET/CT. In the other two patients, bone metastasis could be demonstrated only by 18F–NaF PET/CT. The uptake of 18F-FDG was variable in blastic lesions and cranial bone involvement was missed by 18F-FDG PET/CT in some cases due to physiological brain metabolism. CONCLUSION: Although further prospective clinical studies in specific cancer populations are indicated to set the place of 18F–NaF PET/CT in diagnostic scheme, the results of this pilot study from our country support the superiority of 18F–NaF PET/CT in investigation of bone metastasis over 99mTc-MDP bone scan and 18F-FDG PET/CT in various malignancies. 18F–NaF PET/CT is coming forward as a single step bone seeking study, considering all the advantages, but especially potential of detecting occult metastases and reliably directing patient management. Elsevier 2015-09-16 /pmc/articles/PMC4648995/ /pubmed/26587375 http://dx.doi.org/10.1016/j.jbo.2015.08.002 Text en © 2015 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Araz, Mine
Aras, Gülseren
Küçük, Özlem N.
The role of 18F–NaF PET/CT in metastatic bone disease
title The role of 18F–NaF PET/CT in metastatic bone disease
title_full The role of 18F–NaF PET/CT in metastatic bone disease
title_fullStr The role of 18F–NaF PET/CT in metastatic bone disease
title_full_unstemmed The role of 18F–NaF PET/CT in metastatic bone disease
title_short The role of 18F–NaF PET/CT in metastatic bone disease
title_sort role of 18f–naf pet/ct in metastatic bone disease
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648995/
https://www.ncbi.nlm.nih.gov/pubmed/26587375
http://dx.doi.org/10.1016/j.jbo.2015.08.002
work_keys_str_mv AT arazmine theroleof18fnafpetctinmetastaticbonedisease
AT arasgulseren theroleof18fnafpetctinmetastaticbonedisease
AT kucukozlemn theroleof18fnafpetctinmetastaticbonedisease
AT arazmine roleof18fnafpetctinmetastaticbonedisease
AT arasgulseren roleof18fnafpetctinmetastaticbonedisease
AT kucukozlemn roleof18fnafpetctinmetastaticbonedisease